Syon Biosciences is a pioneering biotech company committed to advancing the field of medicinal chemistry and drug development. With a robust pipeline of 4 novel molecules, we strive to bring next-generation therapies to market, improving patient outcomes and quality of life.

SBS Pitch Deck (2).pdf

July 8, Investor Pitch Deck

Revolutionizing healthcare with cutting-edge research, robust intellectual property, and a pipeline of groundbreaking drug candidates. Join us in transforming scientific discoveries into life-changing treatments.

Pipeline

Syon Biosciences leverages cutting-edge technology platforms to develop our novel molecules. Our research and development efforts focus on harnessing advanced medicinal chemistry, organic synthesis, and biotechnological techniques to create impactful therapies.

AspiNex™

Indication: Inflammation and Cancer
Stage: Preclinical Development
Description: AspiNex™ is a novel acetylating agent targeting NF-kB, a key regulator of inflammatory responses and cancer progression.
Publication: 10.26434/chemrxiv-2024-0m62p

AspiCys™

Indication: Oxidative Stress and Inflammation
Stage: Preclinical Development
Description: AspiCys™ is a promising new drug candidate using the “thiol-switch” mechanism to modulate oxidative stress and inflammatory pathways.
Publication: 10.26434/chemrxiv-2023-wb9m

NaproSalix™

Indication: Cancer and Autoimmune Diseases
Stage: Preclinical Development
Description: NaproSalix™ is a competitive inhibitor of Dihydrofolate Reductase, a critical enzyme in DNA synthesis and repair, making it a potential candidate for cancer and autoimmune disease treatments.
Publication: 10.14293/P2199-8442.1.SOP-.PWB2BX.v1

NaproPax™

Indication: Drug Delivery Enhancement
Stage: Preclinical Development
Description: NaproPax™ is a drug candidate designed to increase absorption through the cell membrane, enhancing the efficacy and bioavailability of therapeutic agents.
Publication: 10.26434/chemrxiv-2023-wlqgg

Stategic Partnerships

We collaborate with leading academic institutions, research organizations, and industry partners to accelerate drug development. These partnerships enhance our capabilities and bring innovative solutions to market faster.

Syon Biosciencies Inc. Is Currently Affiliated With:

ACS (American Chemical Society)
ASBMB (American Society for Biochemistry and Molecular Biology)
Georgia BioEd Insitutite

Leadership

Meet the experienced and dedicated leadership team driving Syon Biosciences forward. Our team comprises experts in biotechnology, medicinal chemistry, and business management, all committed to our mission of improving patient care.

Google Sites

Report abuse